Last update 01 Nov 2024
68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism CD206 inhibitors(Macrophage mannose receptor 1 inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Boost your research with our XDC technology data.
login
or
Related
4
Clinical Trials associated with 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)
A phase II study to evaluate the imaging potential of 68GaNOTA-Anti-MMR VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC).
Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis
100 Clinical Results associated with 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)
Login to view more data
100 Translational Medicine associated with 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)
Login to view more data
100 Patents (Medical) associated with 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)
Login to view more data
100 Deals associated with 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Atherosclerosis | Phase 2 | BE | 26 Jan 2021 | |
| Cardiac sarcoidosis | Phase 2 | BE | 26 Jan 2021 | |
| Carotid Stenosis | Phase 2 | BE | 26 Jan 2021 | |
| Head and Neck Neoplasms | Phase 2 | BE | 26 Jan 2021 | |
| Hodgkin's Lymphoma | Phase 2 | BE | 26 Jan 2021 | |
| Lymphohistiocytosis, Hemophagocytic | Phase 2 | BE | 26 Jan 2021 | |
| Non-Hodgkin Lymphoma | Phase 2 | BE | 26 Jan 2021 | |
| Breast Cancer | Phase 2 | BE | 05 Nov 2019 | |
| Malignant Solid Neoplasm | Phase 2 | BE | 05 Nov 2019 | |
| Melanoma, Cutaneous Malignant | Phase 2 | BE | 05 Nov 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free